Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

Eli Lilly, the pharmaceutical company behind GLP-1 injection Zepbound, is working to bring its weight loss drug to the market in pill form. In an Aug. 7 earnings call, Eli Lilly CEO David ...

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

U.S. stocks drifted to a mixed finish Aug. 8 as President Donald Trump's tariffs taking effect on dozens of countries had ...

But hopes for coming cuts to interest rates by the Federal Reserve and a torrent of stronger-than-expected profit reports from big U.S. companies are helping to offset the concerns, at least for now.

The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...

The S&P 500 slid 0.1% on Thursday, Aug. 7, 2025, as new tariffs took effect, raising import duties on goods from numerous U.S. trading partners.

Eli Lilly’s oral obesity drug orforglipron helped patients lose roughly 11% of their body weight, about 25 pounds, in a ...

U.S. stocks drifted to a mixed finish as President Donald Trump’s tariffs on dozens of countries had only a muted effect on ...